Drugs / LIGHT-PSMA-CART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04053062 | Jul 2020 → May 2022 | castration-resistant prostate carcinoma | Bioray Laboratories | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LIGHT-PSMA-CART | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04053062 ↗ |
| Modality | Cell therapy | “CAR modified autologous T cells” NCT04053062 ↗ |
| Route | Intravenous | “LIGHT-PSMA-CART cells will be given IV at split doses” NCT04053062 ↗ |